Fairvalue-Calculator Fairvalue-Calculator
EN DE

Eurofins-Cerep SA (ALECR) Fair Value & Analysis

Healthcare · FR · Market cap €80.2M

Price€15,300
Fair Value€13,258
Upside-13.3%
Quality95/100
Evidence: High Range €8,751 – €16,573

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Eurofins-Cerep SA (ALECR) currently trades at €15,300, while our model-based Fair Value estimate is €13,258 — implying the stock looks roughly 13.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company's research services include compound management, and high-throughput screening and profiling. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014. Eurofins-Cerep SA was founded in 1989 and is based in Celle-Lévescault, France. Eurofins-Cerep SA is a subsidiary of Eurofins Discovery Services LUX Holding SARL.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -34% Danaher Corporation (DHR) -37% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -54% Lonza Group (LZAGY) -74% Agilent Technologies, Inc (A) -50%

Frequently asked questions

Is Eurofins-Cerep SA (ALECR) undervalued?
As of Jun 24, 2026, our model estimates a fair value of €13,258 versus a price of €15,300 — about −13% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ALECR?
Our 21-model fair value for Eurofins-Cerep SA is €13,258 (as of Jun 24, 2026), built from audited fundamentals. The current price is €15,300.
What is the quality score of ALECR?
Eurofins-Cerep SA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.